🇺🇸 FDA
Patent

US 12331107

Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12331107 (Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody) held by AVALO THERAPEUTICS, INC. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
AVALO THERAPEUTICS, INC.
Grant date
Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K31/706, A61K39/3955